AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs

AstraZeneca's oncology division demonstrated robust performance in the first half of 2025, with sales reaching nearly $12 billion, a 16% year-over-year increase, including an 18% rise to $6.3 billion in Q2. This strong growth, which accounts for 43% of AZN's total revenues, was fueled by established blockbusters like Tagrisso and Lynparza, alongside successful new drug launches such as Truqap ($302M H1 sales) and Datroway ($14M H1 sales). AstraZeneca anticipates continued momentum, projecting an 11.1% CAGR for its oncology portfolio over the next three years, underpinned by a deep pipeline and ongoing label expansions, solidifying its competitive standing against major players like Pfizer, Merck, and Bristol-Myers in the high-growth oncology market.

Analysis

AstraZeneca's oncology division is demonstrating significant growth momentum, solidifying its position as the company's primary value driver. The segment's revenue, which constitutes 43% of the company's total, grew 16% year-over-year in the first half of 2025 to nearly $12 billion, with an acceleration to 18% growth in the second quarter. This performance is fueled by a combination of established blockbusters like Tagrisso and Enhertu, and the successful commercialization of new products. The robust launch of Truqap, which generated $302 million in its first half, and the promising early signals from Datroway ($14 million H1 sales) underscore the company's R&D and market access capabilities. Looking forward, a strong late-stage pipeline and an external forecast projecting an 11.1% compound annual growth rate for the oncology portfolio over the next three years suggest a durable growth trajectory. While the competitive landscape includes formidable players like Merck and Bristol-Myers, AstraZeneca's current oncology growth rate appears to outpace the single-digit growth reported by these peers for their key assets.

Key Decisions for Investors

• Investors should recognize AstraZeneca's oncology segment as the core driver of its investment thesis, given its 16% H1 growth and its contribution of 43% to total company revenue.
• Monitor the sales performance of newly launched drugs Truqap and Datroway, as their successful ramp-up is critical for validating the company's projected 11.1% oncology CAGR and sustaining long-term growth.
• While AstraZeneca shows superior growth, it is crucial to continually assess the competitive oncology landscape, particularly the performance of Merck's Keytruda and Bristol-Myers' Opdivo, and to monitor for any material impact from the U.S. Part D redesign mentioned as a potential headwind.